Literature DB >> 22318132

Posterior reversible encephalopathy syndrome as a revealing manifestation of Guillain-Barré syndrome.

A Etxeberria1, S Lonneville, M-P Rutgers, M Gille.   

Abstract

We report a patient with a Guillain-Barré syndrome (GBS) revealed by a posterior reversible encephalopathy syndrome (PRES). The PRES is typically associated with bilateral parieto-occipital T2 and FLAIR hyperintense MRI lesions and observed in various etiologic conditions leading to acute arterial hypertension. PRES results from a breakdown of the circulatory autoregulation, many in the posterior cerebral territories. GBS can be considered as an independent risk factor of PRES, due to acute dysautonomia and pain with consecutive arterial hypertension, as well as to cytokine production changing capillary permability. Such patients with PRES-revealed GBS may be treated with intravenous immunoglobulin therapy only after exclusion of any ischemic or hemorrhagic cerebral complications, and after control of the blood pressure and of the encephalopathic signs and symptoms.
Copyright © 2012 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22318132     DOI: 10.1016/j.neurol.2011.06.006

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  3 in total

1.  Guillain Barré syndrome-related posterior reversible encephalopathy syndrome.

Authors:  Giulio Zuccoli; Raffaele Nardone; Abdel-Hamid Hoda
Journal:  Neuroradiology       Date:  2015-02-05       Impact factor: 2.804

2.  Posterior reversible encephalopathy syndrome (PRES) as a complication of Guillain-Barre' syndrome (GBS).

Authors:  Sumaira Nabi; Haris Majid Rajput; Mazhar Badshah; Shahzad Ahmed
Journal:  BMJ Case Rep       Date:  2016-08-03

3.  Guillain-Barre syndrome with posterior reversible encephalopathy syndrome.

Authors:  Basavaraj F Banakar; Guruprasad S Pujar; Amita Bhargava; Shubhkaran Khichar
Journal:  J Neurosci Rural Pract       Date:  2014-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.